CURLF · Curaleaf Holdings, Inc. · Financials
Market Cap
$2.53B
Shares
264.81M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.27B
-5%
FY2025
Net Income
-$231.07M
-7.3%
FY2025
Gross Margin
49.76%
+1.7pp
FY2025
Operating Margin
2.01%
+0.2pp
FY2025
Diluted EPS
-$1.05
-9.4%
FY2025
Operating Cash Flow
$137.71M
-15.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| $1.27B | $1.33B | $1.35B | $1.28B | $1.2B | $626.64M | $221.02M | |
| $637.11M | $693.52M | $732.18M | $649M | $626.16M | $311.15M | $102.39M | |
| $631.02M | $640.78M | $614.45M | $626.42M | $569.83M | $390.51M | $141.61M | |
| 49.76% | 48.02% | 45.63% | 49.11% | 47.65% | 62.32% | 64.07% | |
| $805K | $1.42M | — | — | — | — | — | |
| $45.69M | $47.08M | $41.99M | $39.75M | $41.84M | $23.27M | $12.19M | |
| $428.44M | $418.53M | $414.77M | $419.88M | $386.64M | — | — | |
| $100.4M | $109.2M | $105.7M | $92.6M | $71.4M | — | — | |
| $196.61M | $231.46M | $195.88M | $155.98M | $120.54M | $59.92M | $31.7M | |
| $605.57M | $616.03M | $571.57M | $561.43M | $511.26M | — | — | |
| $25.45M | $24.74M | $42.88M | $64.99M | $58.57M | $72.44M | -$27.72M | |
| 2.01% | 1.85% | 3.18% | 5.1% | 4.9% | 11.56% | -12.54% | |
| $222.06M | $256.2M | $238.76M | $220.97M | $179.12M | $132.36M | $3.98M | |
| — | — | — | — | $53.55M | $47.9M | $18.4M | |
| -$103.66M | -$138.1M | -$167.25M | -$151.48M | -$120.77M | — | — | |
| -$1.1M | -$1.8M | — | — | — | — | — | |
| -$78.21M | -$113.36M | -$124.37M | -$86.49M | -$62.2M | $30.8M | -$45.79M | |
| $123.69M | $98.25M | $114.59M | $178.82M | $152.45M | $87.55M | $24.06M | |
| -$231.07M | -$215.42M | -$281.2M | -$370.1M | -$205.94M | -$57.16M | -$67.24M | |
| -18.22% | -16.15% | -20.88% | -29.02% | -17.22% | -9.12% | -30.42% | |
| — | — | — | -$6.83M | -$8.7M | — | — | |
| -$212.8M | -$223.63M | -$274.48M | -$381.95M | -$212.68M | — | — | |
| USD/shares | -$1.05 | -$0.96 | -$1.17 | -$1.56 | -$0.87 | -$0.30 | — |
| USD/shares | -$1.05 | -$0.96 | -$1.17 | -$1.56 | -$0.87 | -$0.30 | — |
| shares | 254.03M | 246.94M | 241.37M | 237.05M | 232.92M | — | — |
| shares | 254.03M | 246.94M | 241.37M | 237.05M | 232.92M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.32×
Peer median 2.13×
EV/EBIT
205.98×
Peer median 17.35×
P/E (TTM)
—
Peer median 15.80×
Peer medians compare against the 44 similar-size Drug Manufacturers - Specialty & Generic companies (of 98 listed).